Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
194
Completed, industry sponsors, Hematology and blood cancers, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed194
194 trials
Showing 1 to 25, recently updated first.
Novartis PharmaceuticalsNovartis (NVS)
NCT01742299 · 155 participants · Start Mar 26, 2013 · Primary completion Apr 20, 2026
Drug: imatinib mesylate · For: GIST and CML
Sites: Los Angeles, California; Chicago, Illinois; Baltimore, Maryland · 29 sites in all
Kyowa Kirin China Pharmaceutical Co., Ltd.Industry
NCT06285370 · 23 participants · Start May 29, 2023 · Primary completion Aug 12, 2025
Drug: Mogamulizumab · For: Cutaneous T-Cell Lymphoma
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 8 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06427811 · 85 participants · Start Nov 28, 2024 · Primary completion Mar 18, 2026
Drug: Asciminib · For: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Sites: Ahmedabad, India; Bengaluru, India; Trivandrum, India · 10 sites in all
AmgenAmgen (AMGN)
NCT03934684 · 101 participants · Start Sep 16, 2019 · Primary completion Mar 23, 2023
Drug: Drug: Carfilzomib + Dexamethasone; Drug: Carfilzomib + Lenalidomide + Dexamethasone · For: Relapsed Refractory Multiple Myeloma
Sites: Hyderabad, India; Bangalore, India; Belagavi, India · 17 sites in all
- Clinical Study on the Treatment of Postpartum Anemia With Compound E Jiao Jiang(cEJJ)Pivotal-lookingCompleted
DongE E Jiao Coporation LimitedIndustry
NCT06175117 · 360 participants · Start Jan 7, 2023 · Primary completion Sep 8, 2025
Drug: compound E Jiao Jiang(cEJJ); compound E Jiao Jiang(cEJJ) placebo · For: Postpartum Anemia
Sites: Beijing, China
- Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence DeficiencyPivotal-lookingCompleted
DongE E Jiao Coporation LimitedIndustry
NCT07270146 · 360 participants · Start Oct 8, 2022 · Primary completion Feb 10, 2025
Drug: Guilu Erxian Oral Liquid; Wuzi Yanzong oral liquid · For: Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency
Sites: Beijing, China
PfizerPfizer (PFE)
NCT05687032 · 44 participants · Start Feb 24, 2023 · Primary completion Aug 7, 2024
Drug: inotuzumab ozogamicin · For: Acute Lymphoblastic Leukemia
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 16 sites in all
BayerBayer (BAYRY)
NCT05036278 · 21 participants · Start Jul 28, 2022 · Primary completion Sep 12, 2024
Drug: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG). · For: Hemophilia A; Prophylaxis of Bleeding
Sites: Loma Linda, California; Los Angeles, California; Aurora, Colorado · 12 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04662931 · 140 participants · Start Jul 14, 2021 · Primary completion Feb 14, 2024
Drug: crizanlizumab · For: Sickle Cell Disease (SCD)
Sites: Guwahati, India; Raipur, India; Kozhikode, India · 7 sites in all
SanofiSanofi (SNY)
NCT05087212 · 53 participants · Start Oct 22, 2021 · Primary completion Dec 6, 2022
Drug: plerixafor + G-CSF · For: Autologous Haematopoietic Stem Cell Transplant
Sites: China, China
TakedaTakeda (TAK)
NCT01909934 · 50 participants · Start Jan 23, 2014 · Primary completion May 4, 2021
Drug: Brentuximab vedotin · For: Lymphoma
Sites: Antwerp, Belgium; Brussels, Belgium; Ghent, Belgium · 40 sites in all
TakedaTakeda (TAK)
NCT05442554 · 10 participants · Start Nov 28, 2022 · Primary completion Aug 9, 2024
Drug: Brentuximab vedotin · For: T-Cell Lymphoma
Sites: Beijing, China; Shanghai, China; Chengdu, China · 4 sites in all
PfizerPfizer (PFE)
NCT04362072 · 71 participants · Start Sep 29, 2020 · Primary completion May 29, 2024
Drug: Lorlatinib · For: Carcinoma; Non-Small-Cell Lung
Sites: Orange, California; New Delhi, India; Bengaluru, India · 31 sites in all
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
NCT03190330 · 75 participants · Start Jun 26, 2019 · Primary completion May 3, 2023
Drug: Ibrutinib 420 mg; Ibrutinib 560 mg · For: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell
Sites: Ahmedabad, India; Chandigarh, India; Hyderabad, India · 10 sites in all
- Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV IronPivotal-lookingCompleted
American Regent, Inc.Industry
NCT01950247 · 1,025 participants · Start Aug 15, 2013 · Primary completion May 20, 2015
Drug: Injectafer; SOC · For: Iron Deficiency Anemia (IDA)
BayerBayer (BAYRY)
NCT04565236 · 45 participants · Start Sep 22, 2020 · Primary completion Mar 15, 2024
Drug: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1; Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2 and 1 more · For: Hemophilia A
Sites: Beijing, China; Hangzhou, China; Shijiazhuang, China · 10 sites in all
Indivior Inc.Industry
NCT04060654 · 17 participants · Start Oct 21, 2019 · Primary completion May 15, 2020
Drug: Sublocade · For: Opioid Use Disorder, Severe; Opioid Use Disorder, Moderate
Sites: Berlin, New Jersey
Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01804166 · 1 participants · Start Mar 21, 2013 · Primary completion Feb 28, 2020
Drug: Infliximab; Golimumab · For: Hepatosplenic T-Cell Lymphoma
Sites: Norfolk, Virginia
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
NCT03768960 · 150 participants · Start Jun 10, 2019 · Primary completion Jul 16, 2022
Drug: Daratumumab · For: Multiple Myeloma
Sites: Ahmedabad, India; Bengaluru, India; Bhubaneswar, India · 16 sites in all
Sobi, Inc.Industry
NCT04638829 · 60 participants · Start Mar 15, 2021 · Primary completion Jan 3, 2024
Drug: Avatrombopag Oral Tablet · For: Immune Thrombocytopenia
Sites: Tucson, Arizona; Whittier, California; Washington D.C., District of Columbia · 20 sites in all
Grifols Biologicals, LLCIndustry
NCT00323856 · 51 participants · Start Apr 8, 2003 · Primary completion Dec 11, 2018
Drug: Alphanate SD/HT · For: Severe Hemophilia A
Sites: Poznan, Poland; Krakow, Poland
AstraZenecaAstraZeneca (AZN)
NCT04930536 · 103 participants · Start Jul 14, 2021 · Primary completion May 2, 2023
Drug: Acalabrutinib capsule · For: Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Sites: Ahmedabad, India; Bangalore, India; Bengaluru, India · 15 sites in all
PfizerPfizer (PFE)
NCT04893811 · 53 participants · Start Aug 18, 2021 · Primary completion Sep 6, 2023
Drug: Trumenba · For: Meningococcal Vaccine
Sites: Brno, Czechia; Prague, Czechia; Bydgoszcz, Poland · 14 sites in all
Swedish Orphan BiovitrumIndustry
NCT03103542 · 16 participants · Start Aug 29, 2017 · Primary completion Sep 4, 2019
Drug: Recombinant coagulation factor (rFVIIIFc) · For: Hemophilia A
Sites: Washington D.C., District of Columbia; Hamilton, Canada; Vancouver, Canada · 12 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04320602 · 18 participants · Start Apr 14, 2021 · Primary completion Dec 20, 2022
Drug: Eculizumab; Ravulizumab · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Leeds, United Kingdom; London, United Kingdom · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.